BACKGROUND: Multilevel spinal fusions have typically been associated with significant @entity190 . Previous studies have shown a reduction in @entity190 with antifibrinolytics in both adolescent and adult @entity85 @entity1 . While this has been mirrored in other subspecialties as well, the dosing of @entity928 remains highly variable. To date, there remains a paucity of data guiding dosing for @entity928 in spine surgery and orthopedic surgery as a whole. METHODS/DESIGN: One hundred and fifty @entity1 from 3 institutions (50 each site) will be consecutively enrolled and randomized to either a high dose of @entity928 (50mg/kg loading followed by 20mg/kg hourly) or a lose dose (10mg/kg, then 1mg/kg hourly). Both surgeons and @entity1 will be blinded to the treatment group. Primary outcomes will be perioperative @entity190 , @entity998 , and transfusion rate. Secondary outcomes will be length of stay, complications, and overall cost. DISCUSSION: The primary goal of this study is to provide level-1 comparative data for two @entity928 dosing regimens in adult @entity85 surgery. Management of @entity190 remains a critical factor in reducing complications during @entity85 surgery. The null hypothesis is that there is no difference between high- and low-dose @entity928 with respect to any of the primary or secondary outcomes.

A Comparison of Two Different Dosing Protocols for Tranexamic Acid in Posterior Spinal Fusion for XXXX : A Prospective, Randomized Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity998 :: ('MESH:D002303', 'Disease') :: ['drain output'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity85 :: ('MESH:D009140', 'Disease') :: ['spinal deformity']
@entity85 :: (MESH:D009140,Disease) :: ['Spinal Deformity']
